JP2021530504A - サリノマイシンを含む高分子ナノ粒子 - Google Patents

サリノマイシンを含む高分子ナノ粒子 Download PDF

Info

Publication number
JP2021530504A
JP2021530504A JP2021501041A JP2021501041A JP2021530504A JP 2021530504 A JP2021530504 A JP 2021530504A JP 2021501041 A JP2021501041 A JP 2021501041A JP 2021501041 A JP2021501041 A JP 2021501041A JP 2021530504 A JP2021530504 A JP 2021530504A
Authority
JP
Japan
Prior art keywords
peg
cancer
poly
pharmaceutical composition
pla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021501041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530504A5 (https=
JPWO2020018778A5 (https=
Inventor
スレンダー・カルバンダー
ジェームズ・ヒル
シリーシュ・アパジョシュラン
マーク・ローゼンバーグ
ハルパル・シン
Original Assignee
ヒルストリーム・バイオファーマ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒルストリーム・バイオファーマ・インコーポレイテッド filed Critical ヒルストリーム・バイオファーマ・インコーポレイテッド
Publication of JP2021530504A publication Critical patent/JP2021530504A/ja
Publication of JP2021530504A5 publication Critical patent/JP2021530504A5/ja
Publication of JPWO2020018778A5 publication Critical patent/JPWO2020018778A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021501041A 2018-07-18 2019-07-18 サリノマイシンを含む高分子ナノ粒子 Pending JP2021530504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699963P 2018-07-18 2018-07-18
US62/699,963 2018-07-18
PCT/US2019/042382 WO2020018778A1 (en) 2018-07-18 2019-07-18 Polymeric nanoparticles comprising salinomycin

Publications (3)

Publication Number Publication Date
JP2021530504A true JP2021530504A (ja) 2021-11-11
JP2021530504A5 JP2021530504A5 (https=) 2022-07-26
JPWO2020018778A5 JPWO2020018778A5 (https=) 2022-07-26

Family

ID=67704555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021501041A Pending JP2021530504A (ja) 2018-07-18 2019-07-18 サリノマイシンを含む高分子ナノ粒子

Country Status (8)

Country Link
US (1) US20200046648A1 (https=)
EP (1) EP3823589A1 (https=)
JP (1) JP2021530504A (https=)
KR (1) KR20210053881A (https=)
CN (1) CN113164375A (https=)
AU (1) AU2019307629A1 (https=)
CA (1) CA3105731A1 (https=)
WO (1) WO2020018778A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186633A1 (en) * 2020-06-30 2022-01-06 Hillstream Biopharma Inc. Nanoparticles and methods of manufacture thereof
WO2022251844A1 (en) * 2021-05-25 2022-12-01 Hillstream Biopharma, Inc. Polymeric nanoparticles comprising chemotherapeutic compounds and related methods
CN116570584B (zh) * 2023-05-08 2025-02-18 广州白云山医药集团股份有限公司白云山制药总厂 盐霉素在制备降尿酸和/或治疗高尿酸血症的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049155A1 (en) * 2016-09-08 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions comprising polymeric nanoparticles and mcl-1 antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165987A1 (en) 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
AU2006278718B2 (en) 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma
KR101445405B1 (ko) 2006-07-28 2014-09-26 가부시키가이샤 브리지스톤 상간 영역을 갖는 중합체성 코어-쉘 나노입자
US20080081075A1 (en) 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
US9149426B2 (en) 2012-02-15 2015-10-06 University Of Tennessee Research Foundation Nanoparticle composition and methods to make and use the same
EP3778696A1 (en) 2012-04-23 2021-02-17 NanoProteagen Ltd. Polymeric nanoparticles and a process of preparation thereof
MY210233A (en) * 2017-10-11 2025-09-04 Illustris Pharmaceuticals Inc Methods and compositions for topical delivery
WO2019104001A1 (en) * 2017-11-22 2019-05-31 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049155A1 (en) * 2016-09-08 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions comprising polymeric nanoparticles and mcl-1 antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INT.J.NANOMEDICINE, vol. 5, JPN6023028878, 2010, pages 1057 - 1065, ISSN: 0005268685 *
PHARM.RES., vol. 32, JPN6023028879, 2015, pages 3756 - 3767, ISSN: 0005268684 *

Also Published As

Publication number Publication date
KR20210053881A (ko) 2021-05-12
AU2019307629A1 (en) 2021-02-18
US20200046648A1 (en) 2020-02-13
WO2020018778A1 (en) 2020-01-23
CN113164375A (zh) 2021-07-23
CA3105731A1 (en) 2020-01-23
EP3823589A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
Han et al. A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer
ES2675212T3 (es) Métodos de tratamiento de carcinoma hepatocelular
ES2447465T3 (es) Partículas de superficie modificada y métodos para la administración dirigida de fármacos
US20210059942A1 (en) Compositions and methods of treating therapy resistant cancer and uses thereof
Qin et al. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis
Chen et al. Co-delivery of doxorubicin and shRNA of Beclin1 by folate receptor targeted pullulan-based multifunctional nanomicelles for combinational cancer therapy
JP2015525245A (ja) ポリマーナノ粒子およびその調整のプロセス
JP2022092069A (ja) ポリマーナノ粒子
JPWO2007088651A1 (ja) ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
Tiwari et al. Increasing the affinity of cationized polyacrylamide-paclitaxel nanoparticles towards colon cancer cells by a surface recognition peptide
Maliyakkal et al. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells
JP2021530504A (ja) サリノマイシンを含む高分子ナノ粒子
WO2018049155A1 (en) Compositions comprising polymeric nanoparticles and mcl-1 antagonists
Feng et al. Oral administration co-delivery nanoparticles of docetaxel and bevacizumab for improving intestinal absorption and enhancing anticancer activity
JP2019537600A (ja) ポリマーナノ粒子
Liu et al. Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma
JP6824535B2 (ja) 脳間質内のナノ粒子分布を改善するための組成物および方法
KR101314579B1 (ko) 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
US20190151340A1 (en) Polymeric nanoparticles comprising bortezomib
WO2022251844A1 (en) Polymeric nanoparticles comprising chemotherapeutic compounds and related methods
Betancourt Targetable biodegradable nanoparticles for delivery of chemotherapeutic and imaging agents to ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240226